Clinical trial NCT05241275: Xenon MRI and Progressive ILD
Official title: XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis
Keywords: Magnetic Resonance Imaging
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Boehringer Ingelheim
First posted: 2022-02-15
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129Xe. The subjects will have this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at 3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat studies will initiate based on time after enrollment.

Detailed description: The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-IPF PF-ILD. Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129Xe. The subjects will have this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at 3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat studies will initiate based on time after enrollment. We plan to consent 75 subjects with PF-ILD who are candidates for anti-fibrotic therapy to slow ILD progression. We will ensure that the study will include at least 38 subjects who start anti-fibrotic therapy after baseline first MRI scan and continue the therapy until his/her 3 month repeat MRI scan. This will be obtained by a pre-specified increase in the number of subjects until the 38 subject criteria is completed. Subject will not be excluded from the study due to stopping anti-fibrotic therapy for any reason during the study.

Additional studies including pulmonary function studies, plasma and serum for biomarkers, whole blood for DNA (baseline visit only), whole blood for RNA, exhaled breath for biomarkers, 6 minute walk distance and a HRCT (only at the screening visit, 6 month visit, and 12 month visit) will be performed to determine how 129Xe MRI performs relative to standard of care evaluations for PF-ILD patients. Finally, following the study visits the research team will prospectively follow the patients' clinical course through periodic reviews of the medical record.

Eligibility criteria: Inclusion Criteria:

* We will include all patients who are over 18 years of age with a physician-diagnosed ILD of one of the below subtypes based on multidisciplinary consensus

  1. Chronic hypersensitivity pneumonitis
  2. Autoimmune interstitial lung disease (including rheumatoid arthritis-ILD, mixed connective tissue disorder related ILD, myositis related ILD, scleroderma related ILD, and idiopathic pneumonia with autoimmune features)
  3. Idiopathic NSIP
  4. Unclassifiable idiopathic interstitial pneumonia
* Fibrotic lung disease affecting more than 10% of lung volume on high-resolution CT, per Duke radiology review
* Evidence of any of the following criteria for progression of ILD within the 24 months before screening:

  1. Relative decline in FVC % predicted of at least 10%
  2. Relative decline in FVC % predicted ≥ 5% - \< 10 combined with either increasing extent of fibrotic changes on HRCT or worsening of respiratory symptoms
  3. Worsening respiratory symptoms and increased extent of fibrosis on HRCT
* Willing and able to give informed consent and adhere to visit/protocol schedules
* Immunosuppressive medication, including azathioprine, cyclosporine, mycophenolate mofetil, rituximab, cyclophosphamide, or oral glucocorticoids are permitted at the discretion of the treating physician

Exclusion Criteria:

* Subject is less than 18 years of age
* Prior treatment with nintedanib or pirfenidone
* Subject is pregnant or lactating
* Prior investigational drug use within 28 days
* MRI is contraindicated based on responses to MRI screening questionnaire
* Respiratory illness of a bacterial or viral etiology within 30 days of MRI
* Acute exacerbation within 30 days of MRI, defined by acute increases in oxygen requirement, bilateral alveolar filling opacities on imaging, and the need for antibiotics and/or systemic steroids
* Subject does not fit into 129Xe vest coil used for MRI
* Subject with ventricular cardiac arrhythmia in the past 30 days.
* Subject has history of cardiac arrest within the last year
* Subject deemed unlikely to be able to comply with instructions during imaging
* Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Primary outcomes:
measure: Change in 129Xe MRI barrier uptake 3 months after anti-fibrotic initiation
timeFrame: Baseline, 3 months
Secondary outcomes:
measure: Change in 129Xe MRI barrier uptake 6 months after anti-fibrotic initiation
timeFrame: Baseline and 6 months
measure: Change in 129Xe MRI RBC to barrier ratio 3 months after anti-fibrotic initiation
timeFrame: Baseline and 3 months
measure: Change in 129Xe MRI RBC to barrier ratio 6 months after anti-fibrotic initiation
timeFrame: Baseline and 6 months
measure: Time to disease progression (occurrence of a ≥ 10% drop in percent predicted FVC, all cause death, or lung transplant) in individuals with elevated barrier uptake at baseline greater than 2 standard deviations of a healthy reference cohort
timeFrame: Up to 12 months
measure: Time to disease progression (occurrence of a ≥ 10% drop in percent predicted FVC, all cause death, or lung transplant) in individuals with decreased RBC transfer at baseline, lower than 2 standard deviations of a healthy reference cohort
timeFrame: Up to 12 months
measure: Time to disease progression (occurrence of a ≥ 10% drop in percent predicted FVC, all cause death, or lung transplant) in individuals with a reduced RBC to barrier ratio, greater than 2 standard deviations of a healthy reference cohort
timeFrame: Up to 12 months
measure: Time to acute exacerbation or respiratory hospitalization in individuals with elevated barrier uptake at baseline greater than 2 standard deviations of a healthy reference cohort
timeFrame: Up to 12 months
measure: Time to acute exacerbation or respiratory hospitalization in individuals with decreased RBC transfer at baseline, lower than 2 standard deviations of a healthy reference cohort
timeFrame: Up to 12 months
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Duke University Health Systems
name: Robert M Tighe, MD
role: PRINCIPAL_INVESTIGATOR
References: